Plasma ACE2 was not statistically significantly different in individuals with COVID‐19 versus those without (8.6 ± 2.5 pg/mL and 3.3 ± 0.9 pg/mL, respectively; Wilcoxon test p = 0.411). This evidence concerns the gene ACE2 and COVID-19.